SCM
CATX icon

Silverarc Capital Management’s Perspective Therapeutics CATX Stock Holding History

Silverarc Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-167,986
Closed -$2.24M – 70
2024
Q3 		$2.24M Sell
167,986
-92,023
-35% -$1.22M 0.5% 48
2024
Q2 		$2.59M Sell
260,009
-550,802
-68% -$7.96M 0.61% 42
2024
Q1 		$9.65M Buy
+810,811
New +$6.91M 2.68% 13

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Silverarc Capital Management's CATX Position: Q4 2024 in Review

Silverarc Capital Management sold out of Perspective Therapeutics (CATX) in Q4 2024, closing a stake of 167,986 shares — an estimated $2.24M sold.

Silverarc Capital Management first reported a position in CATX in Q1 2024 and held it in 3 quarters. The position peaked at $9.65M in Q1 2024. 135 funds tracked by Wall St. Rank hold CATX as of Q4 2024.

  • Silverarc Capital Management reported no remaining Perspective Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 167,986 Perspective Therapeutics shares in Q4 2024, an estimated $2.24M.
  • Silverarc Capital Management first reported a position in Perspective Therapeutics in Q1 2024 and held it in 3 quarters.
  • Silverarc Capital Management's Perspective Therapeutics position peaked at $9.65M in Q1 2024.
  • 135 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q4 2024.

Based on Silverarc Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.